Daily activity relates to not only femoral bone mineral density, but also hip structural analysis parameters: A cross-sectional observational study.

Physical activity to maintain bone mass and strength is important for hip fracture prevention. We aim to investigate the relationship between physical performance/activity status and bone mineral density (BMD)/hip structural analysis (HSA) parameters among postmenopausal women in Japan. Sixty-two postmenopausal women diagnosed with osteoporosis (mean age: 72.61 ± 7.43 years) were enrolled in this cross-sectional observational study. They were evaluated for BMD and HSA in the proximal femur by dual-energy X-ray absorptiometry and underwent several physical performance tests, the Geriatric Locomotive Function Scale of 25 questions (GLFS-25). Principal component analysis (PCA) was used to summarize data on the BMD/HSA parameters. Partial correlation analysis, multiple regression analysis, and structural equation modeling (SEM) were performed to investigate the relationship between physical performance/activity status and BMD/HSA parameters of the proximal femur. In a partial correlation analysis adjusted for age and body mass index (BMI), GLFS-25 scores were correlated with HSA parameter (|r| = 0.260-0.396, P < 0.05). Principal component 1 (PC1) calculated by PCA was interpreted as more reflective of bone strength based on the value of BMD/HSA parameters. The SEM results showed that the model created by the 3 questions (Q13, brisk walking; Q15, keep walking without rest; Q20, load-bearing tasks and housework) of the GLFS-25 had the best fit and was associated with the PC1 score (β = -0.444, P = 0.001). The GLFS-25 score was associated with the BMD/HSA parameter, which may reflect the bone strength of the proximal femur as calculated by PCA.

Informations de copyright

© 2021 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.

Déclaration de conflit d'intérêts

Nobukazu Okimoto has received consulting fees from Teijin Pharma Ltd and Asahi-Kasei Pharmaceutical Co., Ltd. Nobukazu Okimoto has received payments for lectures, such as speakers’ bureau fees, from Astellas Pharma Inc.; Asahi-Kasei Pharmaceutical Co., Ltd.; Eli Lilly Japan K·K.; Chugai Pharmaceutical Co.; Amgen Astellas BioPharma K·K.; Daiichi-Sankyo Co. Ltd.; Eisai Co., Ltd.; Teijin Pharma Ltd.; Pfizer Japan Inc.; Ono Pharmaceutical Co.; and Mitsubishi-Tanabe Pharma Corp. There are no conflicts of interest for all other authors.